Clinical Trial Update: Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial update describes the combination of durvalumab and tremelimumab in cisplatin-ineligible muscle-invasive urothelial cancer, including canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Pelvis Cancer
• Ureter Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING